Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono and Flamel confirm Medusa partnership

Merck Serono and Flamel confirm Medusa partnership

20th December 2007

Merck Serono, a division of Merck KGaA, and Flamel Technologies have confirmed they are to collaborate in the development of Flamel’s Medusa technology.

The two pharmaceuticals firms will investigate the applicability of the technology for the extended release of a therapeutic protein in Merck Serono’s portfolio.

Under the agreement, Flamel will receive an upfront payment of 2 million euros (1.4 million pounds) from Merck for investigating the therapeutic protein as well receiving funds for research and development efforts.

Merck and Flamel have also agreed the financial terms of any potential commercialisation of the formulation.

Bernhard Kirschbaum, Merck Serono’s head of research, expressed the company’s delight in entering into the partnership, highlighting that it gave Merck access to key technology that would improve therapeutic control of its compounds.

“As Flamel’s Medusa technology allows for longer intervals between administrations of injectable proteins compared to standard formulations, we hope to offer an improved convenience for patients requiring treatment by injection,” he indicated.

Flamel’s chief executive officer Stephen H Willard added that the company was pleased to have reached an agreement and that Merck Serono was an “ideal partner” for the project.

Earlier this month, Merck Serono announced that it was to fund a $2 million initiative for research into therapies to alleviate Parkinson’s disease-related cognitive dysfunction and mood disorders.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.